<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cytomegalovirus (CMV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> causes high morbidity and mortality among allogeneic stem cell transplant recipients </plain></SENT>
<SENT sid="1" pm="."><plain>Preemptive therapy with oral valganciclovir or intravenous <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> has replaced universal prophylaxis </plain></SENT>
<SENT sid="2" pm="."><plain>We prospectively studied 19 consecutive adult recipients of allogeneic peripheral blood stem cell transplants from May 2005 through February 2007 to analyze the safety and efficacy of preemptive therapy for the treatment of <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The antigenemia test was persistently negative in 8 patients (42%) and positive at least once in 11 (58%) </plain></SENT>
<SENT sid="4" pm="."><plain>Eight patients were treated with oral valganciclovir on an outpatient basis and they <z:hpo ids='HP_0000001'>all</z:hpo> became CMV negative after the first week of treatment </plain></SENT>
<SENT sid="5" pm="."><plain>The other 3 patients received intravenous <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> and were also CMV negative after the first week of treatment </plain></SENT>
<SENT sid="6" pm="."><plain>No patient abandoned treatment, no severe secondary toxicity was noted, and there was no CMV-associated mortality </plain></SENT>
</text></document>